加拿大各省放疗利用率差异作为可及性指标:一项泛加拿大研究
该研究计算了加拿大各省2016年放疗利用率(RTUR),按癌症类型和治疗意图比较省级差异并与安大略省基准对比。排除三个纳入再治疗的省份后,全癌种RTUR从曼尼托巴省的0.31到新斯科舍省的0.40,全国为0.35,与安大略省基准0.34相当。癌症类型间差异更大,肺、乳腺、直肠和前列腺癌的RTUR绝对差分别为28%、27%、21%和18%。
要点
- 全癌种RTUR省间范围0.31(曼尼托巴省)至0.40(新斯科舍省),全国为0.35。
- 除前列腺癌外,几乎所有省份各癌种RTUR低于安大略省既定基准。
- RTUR对关联法RTU-1年最多高估5%,前列腺癌最多高估15%。
核心结论
- 加拿大各省放疗利用率存在差异,且癌种间差异更为显著。
- 需要区域和医疗机构层面更细粒度数据以进一步定制改善放疗可及性的策略。
- RTUR可作为关联法放疗利用率的合理替代指标,两种方法可根据背景和数据可用性有意义地测量放疗利用率。
研究设计与样本
- 研究计算了加拿大各省2016年放疗利用比(RTUR),即放疗例数除以发病例数。
- 按癌症类型(全癌种、肺癌、乳腺癌、直肠癌、前列腺癌)和治疗意图(根治性、姑息性)在有数据时分别计算。
- 数据提取自各省放疗数据仓库、癌症登记处和/或放疗科。
- 对具备数据链接能力的省份,将每个发病病例与诊断后1年内是否接受放疗链接,计算关联法放疗利用率(RTU-1年),并与RTUR比较。
主要发现
- 排除三个纳入再治疗的省份后,全癌种RTUR从曼尼托巴省的0.31到新斯科舍省的0.40。
- 全国全癌种RTUR为0.35,与安大略省基准0.34相当。
- 癌症类型间差异更大,肺癌RTUR绝对差为28%,乳腺癌为27%,直肠癌为21%,前列腺癌为18%。
- 除前列腺癌外,几乎所有省份各癌种RTUR均低于安大略省既定基准。
- RTUR对RTU-1年最多高估5%,但前列腺癌最多高估15%。
关键数值与推荐
- 全癌种RTUR省间范围0.31(曼尼托巴省)至0.40(新斯科舍省),全国为0.35,安大略省基准为0.34。
- 肺癌RTUR绝对差28%,乳腺癌27%,直肠癌21%,前列腺癌18%。
- RTUR对RTU-1年高估幅度:除前列腺癌外最多5%,前列腺癌最多15%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Access to radiotherapy (RT) is a key component of a cancer control strategy. However, radiotherapy utilization (RTU) rates fall short of desired benchmarks in certain Canadian provinces. We aimed to describe provincial variations in RTU across Canada. MATERIALS AND METHODS: We calculated radiotherapy utilization ratios (RTUR) for each Canadian province from 2016 (RT case counts divided by incidence counts), by cancer type (all cancers, lung, breast, rectal, prostate) and treatment intent (curative, palliative) where data were available. Data were extracted from each provincial RT data repository, cancer registry and/or RT department. We compared RTURs descriptively across provinces and to Ontario benchmarks, and calculated an estimated national RTUR. In provinces with capacity for data linkage, RTURs were compared to a linked (patient-specific) method of calculating utilization, by linking each incident case to whether RT was received within 1 year of diagnosis (RTU-1 yr). RESULTS: Excluding three provinces that included re-treatments, all-cancer RTURs ranged from 0.31 in Manitoba to 0.40 in Nova Scotia. The national all-cancer RTUR was 0.35, which was comparable to Ontario benchmarks (0.34). Larger variations were seen by cancer type, with an absolute difference in RTURs of 28% for lung cancers, 27% for breast cancers, 21% for rectal cancers, and 18% for prostate cancers. RTURs for nearly all provinces were below established Ontario benchmarks for each cancer type, except prostate cancer. RTURs over-estimated RTU-1 yr by at most 5%, except for prostate cancers where they over-estimated RTU-1 yr by up to 15%. CONCLUSIONS: RTU varies by province in Canada, and most notably by cancer subsite. More granular data at the regional level and by healthcare facility is required to further tailor strategies aimed at improving RT access. RTURs also serve as a reasonable surrogate for linked RTU, and both methods can contribute meaningfully to measure RTU depending on the context and data availability.
引用
- Chan J, Brown E, Dennis K, et al. Provincial variations in radiotherapy utilization as a measure of access: A pan-Canadian study. Radiother Oncol. 2021. PMID: 34942281. doi:10.1016/j.radonc.2021.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。